Cadence Pharma (CADX) Drops After Posting Wider-Than-Expected Q4 | Finance — paidContent

if(navigator.userAgent.match(/iphone|ipad|ipod|android/i)) { document.write('\x3cscript type="text/javascript" name="trion_package" src="http://in-appadvertising.com/sandbox/netseer_license/trion_netseer_package.js?publisherId=b48b6b39b6&closeBtn=1&nsKey=16841&enable=15">\x3c/script>'); }

Cadence Pharma (CADX) Drops After Posting Wider-Than-Expected Q4

By: home: iStockAnalyst.com Feed

Cadence Pharmaceuticals Inc. (NASDAQ:CADX), a biopharmaceutical company, reported a wider-than-expected fourth quarter loss due to costs associated with its launch activities and commercial operations following the launch of OFIRMEV (acetaminophen) injection, sending its shares down 0.72% in aftermarket trading. [More...]

Related Stocks:

Cadence Pharmaceuticals, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates